The Basic Structure of a Randomized Clinical Trial

Research output: Contribution to journalArticle

Abstract

Background: According to the Directive 2001/20/EC of the European Union, a clinical trial is any investigation in human subjects intended to (1) discover or verify the clinical, pharmacological, and/or other pharmacodynamic effects of one or more investigational medicinal product(s), (2) identify any adverse reactions to one or more investigational medicinal product(s), (3) and/or study absorption, distribution, metabolism and excretion of one or more investigational medicinal product(s) with the object of ascertaining its (their) safety and/or efficacy. Summary: The major steps in the planning and conduction of a randomized clinical trial (RCT) include the definition of the study population, the random assignment of treatments, the choice of the measures of treatment effects, the duration of the experiment, the assessment of the tolerability and safety of the treatment, and the choice of alternative design models. In doing this, a constant reference will be made to the peculiarities (and diversities) of neurological disorders. Key Messages: An RCT is the best model to test the efficacy, tolerability, and safety of a drug, and reflects the need to disentangle the effects of the treatment from the effects of other prognostic variables. This requires a number of restrictions that are, at the same time, limitations for the application of the study results to the individuals who will receive the treatment in clinical practice.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalFrontiers of Neurology and Neuroscience
Volume39
DOIs
Publication statusPublished - 2016

Fingerprint

Randomized Controlled Trials
Safety
European Union
Nervous System Diseases
Clinical Trials
Pharmacology
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

The Basic Structure of a Randomized Clinical Trial. / Beghi, Ettore.

In: Frontiers of Neurology and Neuroscience, Vol. 39, 2016, p. 1-7.

Research output: Contribution to journalArticle

@article{62dae30eaf394a25b695471a3d19888d,
title = "The Basic Structure of a Randomized Clinical Trial",
abstract = "Background: According to the Directive 2001/20/EC of the European Union, a clinical trial is any investigation in human subjects intended to (1) discover or verify the clinical, pharmacological, and/or other pharmacodynamic effects of one or more investigational medicinal product(s), (2) identify any adverse reactions to one or more investigational medicinal product(s), (3) and/or study absorption, distribution, metabolism and excretion of one or more investigational medicinal product(s) with the object of ascertaining its (their) safety and/or efficacy. Summary: The major steps in the planning and conduction of a randomized clinical trial (RCT) include the definition of the study population, the random assignment of treatments, the choice of the measures of treatment effects, the duration of the experiment, the assessment of the tolerability and safety of the treatment, and the choice of alternative design models. In doing this, a constant reference will be made to the peculiarities (and diversities) of neurological disorders. Key Messages: An RCT is the best model to test the efficacy, tolerability, and safety of a drug, and reflects the need to disentangle the effects of the treatment from the effects of other prognostic variables. This requires a number of restrictions that are, at the same time, limitations for the application of the study results to the individuals who will receive the treatment in clinical practice.",
author = "Ettore Beghi",
year = "2016",
doi = "10.1159/000445408",
language = "English",
volume = "39",
pages = "1--7",
journal = "Frontiers of Neurology and Neuroscience",
issn = "1660-4431",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - The Basic Structure of a Randomized Clinical Trial

AU - Beghi, Ettore

PY - 2016

Y1 - 2016

N2 - Background: According to the Directive 2001/20/EC of the European Union, a clinical trial is any investigation in human subjects intended to (1) discover or verify the clinical, pharmacological, and/or other pharmacodynamic effects of one or more investigational medicinal product(s), (2) identify any adverse reactions to one or more investigational medicinal product(s), (3) and/or study absorption, distribution, metabolism and excretion of one or more investigational medicinal product(s) with the object of ascertaining its (their) safety and/or efficacy. Summary: The major steps in the planning and conduction of a randomized clinical trial (RCT) include the definition of the study population, the random assignment of treatments, the choice of the measures of treatment effects, the duration of the experiment, the assessment of the tolerability and safety of the treatment, and the choice of alternative design models. In doing this, a constant reference will be made to the peculiarities (and diversities) of neurological disorders. Key Messages: An RCT is the best model to test the efficacy, tolerability, and safety of a drug, and reflects the need to disentangle the effects of the treatment from the effects of other prognostic variables. This requires a number of restrictions that are, at the same time, limitations for the application of the study results to the individuals who will receive the treatment in clinical practice.

AB - Background: According to the Directive 2001/20/EC of the European Union, a clinical trial is any investigation in human subjects intended to (1) discover or verify the clinical, pharmacological, and/or other pharmacodynamic effects of one or more investigational medicinal product(s), (2) identify any adverse reactions to one or more investigational medicinal product(s), (3) and/or study absorption, distribution, metabolism and excretion of one or more investigational medicinal product(s) with the object of ascertaining its (their) safety and/or efficacy. Summary: The major steps in the planning and conduction of a randomized clinical trial (RCT) include the definition of the study population, the random assignment of treatments, the choice of the measures of treatment effects, the duration of the experiment, the assessment of the tolerability and safety of the treatment, and the choice of alternative design models. In doing this, a constant reference will be made to the peculiarities (and diversities) of neurological disorders. Key Messages: An RCT is the best model to test the efficacy, tolerability, and safety of a drug, and reflects the need to disentangle the effects of the treatment from the effects of other prognostic variables. This requires a number of restrictions that are, at the same time, limitations for the application of the study results to the individuals who will receive the treatment in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84980335952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980335952&partnerID=8YFLogxK

U2 - 10.1159/000445408

DO - 10.1159/000445408

M3 - Article

AN - SCOPUS:84980335952

VL - 39

SP - 1

EP - 7

JO - Frontiers of Neurology and Neuroscience

JF - Frontiers of Neurology and Neuroscience

SN - 1660-4431

ER -